Fish Anthelmintics Drugs Market Size & Share 2026-2035

Fish Anthelmintics Drugs Market Size

The global fish anthelmintics drugs market size was estimated at USD 256 million in 2025. The market is expected to grow from USD 269.4 million in 2026 to USD 430.5 million in 2035, at a CAGR of 5.3% during the forecast period, according to the latest report published by Global Market Insights Inc.

The addressable demand is tied to the growing concentration of fish biomass in managed production systems, where parasite exposure can affect growth, feed utilization, survival, and harvest timing. Global aquaculture production surpassed 100 million tonnes for the first time in 2024, reaching approximately 103 million tonnes, reinforcing the scale of the production base that requires aquatic animal-health management ^{[1]fao.org - SOFIA 2026: Global fisheries and aquaculture production reaches new highs}.

Parasite-control demand is not determined by production volume alone. High stocking density, repeated water use, and movement of fish among hatcheries, grow-out sites, and processing networks can increase exposure to nematodes, trematodes, cestodes, and mixed infections. Research on global mariculture has identified both protistan and metazoan parasites as sources of material economic losses, particularly where infection impairs growth or elevates mortality risk ^{[2]cambridge.org - Economic costs of protistan and metazoan parasites to global mariculture}. This makes treatment selection a production-management decision rather than a purely veterinary purchase.

Food-safety controls also shape the market's commercial boundary. Codex maintains maximum-residue-limit provisions for veterinary drugs in foods, including relevant fish commodities, requiring treatment programs to account for compound selection, dosage, withdrawal periods, and residue monitoring ^{[3]fao.org - Codex Alimentarius veterinary drugs database}. Products that can demonstrate effective parasite control while fitting farm-level residue-management requirements are therefore better positioned in regulated aquaculture supply chains.

Key Drivers

Rising production of aquaculture

Aquaculture expansion enlarges the population of fish requiring organized parasite surveillance and treatment. The effect is particularly pronounced in intensive systems, where intervention must be compatible with large stocks and narrow operational windows. Oral treatments incorporated into medicated feeds are commercially important because they can reach fish populations without repeated handling, while immersion treatments offer a practical response where external parasites require rapid population-level treatment.

Surging prevalence of parasitic diseases

Helminth infection can create a direct production penalty through impaired feeding, slower weight gain, tissue damage, and greater susceptibility to secondary disease. The economic consequences are amplified when parasites occur alongside other health stressors, because mixed infections complicate treatment selection and may require broader-spectrum management. The market therefore benefits from demand for therapies that fit identified parasite profiles rather than indiscriminate chemical use.

Development of long-acting formulations and combination therapies

Formulation development is changing the operational value of anthelmintics. Coated pellets, controlled-release feed systems, and water-soluble products can improve dose stability and reduce handling demands. Combination approaches may be useful when co-infections involve parasites with different life cycles, but their adoption depends on compatible residue, environmental, and regulatory assessments. These constraints reward suppliers that can convert pharmacological efficacy into practical protocols for hatcheries and grow-out farms.

Stringent food safety regulations

Residue requirements create demand for treatment programs that can be documented from procurement through harvest. Codex maximum-residue-limit standards make veterinary-drug stewardship relevant to exporters and integrated producers, especially where fish enter formal retail, food-service, or cross-border channels ^{[3]fao.org - Codex Alimentarius veterinary drugs database}. Regulatory scrutiny can support demand for approved and traceable products, even as it raises the compliance burden for suppliers.

Key Restraints

Strict approval processes for new veterinary drugs

The approval pathway can slow the conversion of a promising aquatic-health compound into a commercially available treatment. In the United States, FDA identifies most fish as minor species, a classification that affects the availability and development economics of approved drugs ^{[4]fda.gov - FDA answers your questions about fish drugs}. The U.S. Fish and Wildlife Service also notes that the cost and complexity of aquatic-animal drug approval can discourage sponsors from pursuing products for comparatively small commercial markets ^{[5]fws.gov - How an aquatic animal drug is approved in the United States}.

European suppliers face similarly rigorous requirements. Veterinary medicines require marketing authorization, and products intended for farmed finfish must meet species- and use-specific safety and efficacy expectations ^{[6]ema.europa.eu - Marketing authorisation for veterinary medicines}. Approval lead times can favor established actives and suppliers with regulatory capability, limiting the pace at which newer formulations enter the market.

Concerns regarding residual drugs in water bodies

Environmental persistence constrains treatment decisions, particularly in open-water and recirculating systems. Research has reported albendazole persistence in sediment associated with yellowtail aquaculture, while separate aquaculture-site research detected praziquantel in water and sediment ^{[8]doi.org - Albendazole sediment persistence in yellowtail aquaculture (Aquaculture Reports)}. Ivermectin has also shown persistence in simulated aquaculture ecosystems ^{[10]onlinelibrary.wiley.com - Ivermectin persistence in a simulated aquaculture ecosystem (Aquaculture Research)}. These findings do not establish identical environmental behavior across all compounds or farming conditions, but they reinforce the need for molecule-specific environmental management.

Environmental risk assessment is mandatory for veterinary medicines in the European authorization framework ^{[9]mdpi.com - Praziquantel detection in water and sediment at an aquaculture site (Fishes)}. Compliance pressures can shift purchasing toward treatments supported by discharge controls, documented dosing, and environmental-risk evidence, while farms with limited monitoring capability may delay or restrict use.

Fish Anthelmintics Drugs Market Segment Analysis

By Drug Class

Pyrazinoisoquinolones held the largest market share at 46.31% in 2024 and are projected to grow at a 5.14% CAGR through 2035. Their leading position reflects the relevance of praziquantel-based treatment in trematode and cestode management, including applications involving salmon and ornamental fish. Benzimidazoles accounted for 25.58% of 2024 revenue and remain important for nematode and fluke management where broad-spectrum activity and lower treatment cost are prioritized.^[7]

Macrocyclic lactones represented 18.58% of the market in 2024 but are forecast to advance at the fastest drug-class CAGR of 6.29%. Their higher projected growth signals demand for alternatives where parasite-control programs require differentiated modes of action. Other drug classes accounted for 9.52%, retaining relevance in specialized species, treatment settings, and parasite profiles.

By Target Parasite

Nematodes accounted for 31.76% of the market in 2024 and are forecast to grow at 6.06%, the highest rate among parasite segments. Their commercial importance stems from the effect of intestinal infection on growth and feed conversion, which directly influences farm economics. Trematodes represented 30.96% of revenue, reflecting the management burden created by infections affecting gills, skin, and internal organs.

Mixed infections accounted for 24.03% of the market. This segment presents a distinct treatment challenge because parasite species can differ in location, life cycle, and susceptibility. Cestodes represented 13.25%, with demand concentrated in treatment programs requiring control of intestinal parasite burdens.

By Formulation

Oral products generated 60.47% of market revenue in 2024. Their dominance is linked to medicated-feed delivery, which allows farms to treat large populations over extended periods while reducing individual fish handling. Formulation stability is central to this channel because pellet integrity and reduced drug leaching influence both dose consistency and environmental exposure.

Immersion products held a 36.24% share and are expected to grow at 6.02% through 2035. Their role is strongest when population-wide treatment is required quickly, particularly for external parasites and early-life-stage fish. Injectable products accounted for only 3.29%, reflecting their limited suitability for high-volume farming operations.

By Distribution Channel

B2B distribution represented 49.59% of market revenue in 2024. Large farms and feed manufacturers use this channel to procure treatment volumes aligned with production cycles, veterinary protocols, and feed-delivery arrangements. Such relationships can increase the importance of formulation reliability and supplier technical support.

Veterinary pharmacies held a 30.75% share and are forecast to expand at 6.13% annually. Their role is significant in more complex cases requiring diagnosis, dose selection, and access to specialized formulations. E-commerce is expected to post the fastest channel growth at 6.48%, although its 7.35% 2024 share indicates that online access remains complementary to veterinary oversight and formal farm procurement. Retail stores accounted for 12.31% of revenue, with greater relevance in ornamental-fish and smaller-farm settings.

Fish Anthelmintics Drugs Market Regional Analysis

Asia Pacific

Asia Pacific held a 75.30% share of the global market in 2024, equivalent to USD 184.32 million, and is forecast to grow at a 5.47% CAGR through 2035. China, India, Indonesia, and Vietnam provide a large production base, while demand varies by cultured species, farming intensity, and access to veterinary infrastructure. China's aquaculture-health challenge includes concerns over antimicrobial resistance and environmental residues. Research has documented antimicrobial-resistance genes in aquaculture sediments across five Chinese provinces, while monitoring research has identified 19 anthelmintic classes in Chinese river water and sediment. These pressures support interest in more targeted treatment, stronger disease surveillance, and lower-impact health-management practices.

India's expanding aquaculture output provides a growing treatment base. Production increased from 4.8 million metric tonnes to 10.2 million metric tonnes between 2015 and 2022, according to the country data reported through the World Organisation for Animal Health. The increase in inland fisheries and aquaculture production creates a commercial case for products adapted to local species and farm economics, rather than formulations designed only for large salmonid operations.

Europe

Europe accounted for 9.20% of global market revenue in 2024. European aquaculture production is concentrated: the five largest species represented 96% of production in 2022. This concentration can make health events commercially significant because a limited set of species and production systems drives a large share of regional output. Norway's salmon industry is particularly consequential for aquatic-health suppliers. Its traffic-light system evaluates 13 production areas based on sea-lice-related environmental impact, with production capacity affected by the assigned color classification. BarentsWatch Fish Health further supports monitoring by compiling disease, parasite, and welfare information from multiple data sources.

Middle East and Africa

The Middle East and Africa market was valued at USD 18.11 million in 2024 and is projected to record the fastest regional CAGR of 6.33%. Egypt is a major regional anchor. USDA reporting identifies Egypt as Africa's leading aquaculture producer, with Nile tilapia central to production. Demand growth in the region is likely to depend on whether fish-health programs become more integrated with farm biosecurity, diagnostics, and extension support.

Latin America

Latin America accounted for USD 13.71 million in 2024. Brazil is central to regional demand because its freshwater aquaculture systems support diverse host-parasite relationships. A systematic review identified 286 myxozoan taxa in Brazilian fish, while noting that only about 3% of known fish species have been surveyed. The evidence points to a diagnostic gap as well as a treatment opportunity: broader product availability alone will not resolve losses where parasite identification and farm-level surveillance remain limited.

North America

North America represented 2.50% of the global market in 2024, or USD 6.12 million, and is projected to grow at a 4.42% CAGR. The U.S. accounted for 81.91% of regional revenue, while Canada represented 18.09%. Fish-drug availability is shaped by a demanding regulatory environment, with FDA oversight and minor-species economics affecting development incentives ^{[4]fda.gov - FDA answers your questions about fish drugs}. Consequently, the region's commercial opportunity is concentrated in technically supported, approved treatment programs for species such as salmon and trout rather than broad, low-cost product distribution.

Fish Anthelmintics Drugs Market Share & Competitive Landscape

The market is fragmented, combining multinational animal-health suppliers with regional fish-health specialists and suppliers serving ornamental and smaller commercial farms. Competition centers on formulation performance, breadth of parasite coverage, administration practicality, regulatory compliance, and the ability to support farm-level treatment protocols.

Merck & Co., Inc. strengthened its aquaculture-health position through the acquisition of Elanco Animal Health's aqua business. The transaction added products including CLYNAV®, a DNA-based salmon vaccine, and IMVIXA®, a sea-lice antiparasitic, broadening Merck Animal Health's aquaculture portfolio beyond individual therapeutic products. The expanded platform increases the importance of integrated offerings that combine parasite control with vaccines, biosecurity, and production monitoring.

Aquatic Remedies is positioned toward affordable water treatments and health supplements for small-to-medium aquaculture farms. Its competitive relevance depends on distribution reach, farm education, and the ability to translate treatment options into workable husbandry practices for operators with limited access to specialized aquatic-health services.

Syndel participates through therapeutics, anesthetics, and biosecurity solutions. In regulated aquaculture markets, suppliers with product-quality systems and compliance capability can compete on more than active ingredients, particularly when producers require reliable treatment documentation and disease-prevention support.

The approved competitive scope also includes API, Aquarium Products India, Centurion HEALTHCARE, Hikari, KOI PHARMA, Kyoritsu Seiyaku Corporation, NATIONAL FISH PHARMACEUTICALS U.S.A., and other named suppliers. Their market roles differ by species focus, geography, formulation format, and customer channel. For specialty and ornamental applications, distribution access and product usability may matter more than the scale advantages that shape B2B procurement for intensive food-fish farming.

Recent Industry Developments

• On February 5, 2024, Merck Animal Health announced a definitive agreement to acquire Elanco Animal Health's aqua business for approximately USD 1.3 billion. Merck completed the acquisition on July 9, 2024, formally incorporating the acquired aqua portfolio into its animal-health operations.

• In March 2024 trade reporting, Koi Pharma was reported to have debuted a pond and fish-health portfolio at the Water Garden Expo held in late February and early March. The range included Pure Prazi - Fluke Eliminator, Pure Broad Spectrum, Bacterial Control Koi Food, and Pure Nitro. Koi Pharma's official website also lists fish-health product offerings.